Cellectis (NASDAQ:CLLS) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.
Volatility and Risk
Cellectis has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500.
33.3% of Cellectis shares are held by institutional investors. Comparatively, 25.1% of Idera Pharmaceuticals shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 3.5% of Idera Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Cellectis and Idera Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellectis||$22.99 million||42.98||-$102.09 million||($2.41)||-9.65|
|Idera Pharmaceuticals||$1.45 million||110.37||-$56.51 million||($1.57)||-2.89|
Idera Pharmaceuticals has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and target prices for Cellectis and Idera Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cellectis currently has a consensus target price of $24.25, indicating a potential upside of 4.26%. Idera Pharmaceuticals has a consensus target price of $9.00, indicating a potential upside of 98.24%. Given Idera Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Idera Pharmaceuticals is more favorable than Cellectis.
This table compares Cellectis and Idera Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.
About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Exton, Pennsylvania.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.